Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia

Psychiatry Research

Volumn 210, Issue 3, 2013, Pages 825-829

  Chen, Song ^a   Broqueres You, Dong ^a,b   Yang, Guigang ^a   Wang, Zhiren ^a   Li, Yanli ^a   Wang, Ning ^a   Zhang, Xiangyang ^a,c   Yang, Fude ^a   Tan, Yunlong ^a  

^a BEIJING HUILONGGUAN HOSPITAL   (China)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic naive first episode psychosis schizophrenia; Dyslipidaemia; Insulin resistance; Psychopathology

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; HALOPERIDOL; INSULIN; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIACYLGLYCEROL; GLUCOSE; GLUCOSE BLOOD LEVEL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY MASS; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MENTAL DISEASE; MULTIPLE LINEAR REGRESSION ANALYSIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CASE CONTROL STUDY; CHINA; DRUG EFFECTS; EPIDEMIOLOGY; ETHNOLOGY; GLUCOSE TOLERANCE TEST; METABOLISM; PATHOLOGY; PSYCHOTIC DISORDERS; REGRESSION ANALYSIS; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; CHINA; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; PSYCHOPATHOLOGY; PSYCHOTIC DISORDERS; REGRESSION ANALYSIS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84888300074     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.08.056     Document Type: Article

References (39)

1. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., Navarro M.A., San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. The Journal of Clinical Psychiatry 2004, 65:1335-1342.
2. Barrett-Connor E., Giardina E.G., Gitt A.K., Gudat U., Steinberg H.O., Tschoepe D. Women and heart disease: the role of diabetes and hyperglycemia. Archives of Internal Medicine 2004, 164:934-942.
3. Barros R.P., Gustafsson J.A. Estrogen receptors and the metabolic network. Cell Metabolism 2011, 14:289-299.
4. Barros R.P., Machado U.F., Gustafsson J.A. Estrogen receptors: new players in diabetes mellitus. Trends in Molecular Medicine 2006, 12:425-431.
5. Brennan A.M., Mantzoros C.S. Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications. Nature Clinical Practice. Endocrinology & Metabolism 2006, 2:318-327.
6. Brown S. Excess mortality of schizophrenia. A meta-analysis. The British Journal of Psychiatry: the Journal of Mental Science 1997, 171:502-508.
7. Chen da C., Wang J., Wang B., Yang S.C., Zhang C.X., Zheng Y.L., Li Y.L., Wang N., Yang K.B., Xiu M.H., Kosten T.R., Zhang X.Y. Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 2009, 207:375-380.
8. Chen da C., Zhou M.A., Zhou D.H., Xiu M.H., Wu G.Y., Kosten T.R., Zhang X.Y. Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics. Psychiatry Research 2011, 186:451-453.
9. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. The Journal of Clinical Psychiatry 2006, 67:575-583.
10. Coryell W., Tsuang D. Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow-up. The American Journal of Psychiatry 1992, 149:1033-1039.
11. Curkendall S.M., Mo J., Glasser D.B., Rose Stang M., Jones J.K. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. The Journal of Clinical Psychiatry 2004, 65:715-720.
12. Dore S., Kar S., Quirion R. Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:4772-4777.
13. Finan B., Yang B., Ottaway N., Stemmer K., Muller T.D., Yi C.X., Habegger K., Schriever S.C., Garcia-Caceres C., Kabra D.G., Hembree J., Holland J., Raver C., Seeley R.J., Hans W., Irmler M., Beckers J., de Angelis M.H., Tiano J.P., Mauvais-Jarvis F., Perez-Tilve D., Pfluger P., Zhang L., Gelfanov V., DiMarchi R.D., Tschop M.H. Targeted estrogen delivery reverses the metabolic syndrome. Nature Medicine 2012, 18:1847-1856.
14. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA: The Journal of the American Medical Association 2002, 287:356-359.
15. Garcia-Tornadu I., Ornstein A.M., Chamson-Reig A., Wheeler M.B., Hill D.J., Arany E., Rubinstein M., Becu-Villalobos D. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 2010, 151:1441-1450.
16. Herrman H.E., Baldwin J.A., Christie D. A record-linkage study of mortality and general hospital discharge in patients diagnosed as schizophrenic. Psychological Medicine 1983, 13:581-593.
17. Kay S.R., Opler L.A., Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. The British Journal of Psychiatry 1989, 59-67. (Supplement).
18. Kirkpatrick B., Fernandez-Egea E., Garcia-Rizo C., Bernardo M. Differences in glucose tolerance between deficit and nondeficit schizophrenia. Schizophrenia Research 2009, 107:122-127.
19. Krabbe K.S., Nielsen A.R., Krogh-Madsen R., Plomgaard P., Rasmussen P., Erikstrup C., Fischer C.P., Lindegaard B., Petersen A.M., Taudorf S., Secher N.H., Pilegaard H., Bruunsgaard H., Pedersen B.K. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007, 50:431-438.
20. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., Salonen J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA: The Journal of the American Medical Association 2002, 288:2709-2716.
21. Lammers C.H., Garcia-Borreguero D., Schmider J., Gotthardt U., Dettling M., Holsboer F., Heuser I.J. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biological Psychiatry 1995, 38:803-807.
22. Lindenmayer J.P., Nathan A.M., Smith R.C. Hyperglycemia associated with the use of atypical antipsychotics. The Journal of Clinical Psychiatry 2001, 62(Suppl 23):30-38.
23. Mohan D., Gordon H., Hindley N., Barker A. Schizophrenia and diabetes mellitus. The British Journal of Psychiatry 1999, 174:180-181.
24. Nakagawa T., Ono-Kishino M., Sugaru E., Yamanaka M., Taiji M., Noguchi H. Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice. Diabetes/Metabolism Research and Reviews 2002, 18:185-191.
25. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
26. Newcomer J.W., Ratner R.E., Eriksson J.W., Emsley R., Meulien D., Miller F., Leonova-Edlund J., Leong R.W., Brecher M. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. The Journal of Clinical Psychiatry 2009, 70:487-499.
27. Rubi B., Ljubicic S., Pournourmohammadi S., Carobbio S., Armanet M., Bartley C., Maechler P. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. The Journal of Biological Chemistry 2005, 280:36824-36832.
28. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. The American Journal of Psychiatry 2003, 160:284-289.
29. Ryan M.C., Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sciences 2002, 71:239-257.
30. Sengupta S., Parrilla-Escobar M.A., Klink R., Fathalli F., Ying Kin N., Stip E., Baptista T., Malla A., Joober R. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls?. Schizophrenia Research 2008, 102:329-336.
31. Shankar E., Santhosh K.T., Paulose C.S. Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro. IUBMB Life 2006, 58:157-163.
32. Shi H., Clegg D.J. Sex differences in the regulation of body weight. Physiology and Behavior 2009, 97:199-204.
33. van Os J., Kapur S. Schizophrenia. The Lancet 2009, 374:635-645.
34. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Naveen M.N., Thirthall J., Gangadhar B.N., Shetty K.T. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. The American Journal of Psychiatry 2007, 164:1557-1560.
35. Verma S.K., Subramaniam M., Liew A., Poon L.Y. Metabolic risk factors in drug-naive patients with first-episode psychosis. The Journal of Clinical Psychiatry 2009, 70:997-1000.
36. Wang H.C., Yang Y.K., Chen P.S., Lee I.H., Yeh T.L., Lu R.B. Increased plasma leptin in antipsychotic-naive females with schizophrenia, but not in males. Neuropsychobiology 2007, 56:213-215.
37. Yamanaka M., Itakura Y., Tsuchida A., Nakagawa T., Taiji M. Brain-derived neurotrophic factor (BDNF) prevents the development of diabetes in prediabetic mice. Biomedical Research 2008, 29:147-153.
38. Yamanaka M., Tsuchida A., Nakagawa T., Nonomura T., Ono-Kishino M., Sugaru E., Noguchi H., Taiji M. Brain-derived neurotrophic factor enhances glucose utilization in peripheral tissues of diabetic mice. Diabetes, Obesity and Metabolism 2007, 9:59-64.
39. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 2005, 30:1532-1538.